{"filing":{"accession_number":"0001503802-26-000027","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"kpti-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000150380226000027/kpti-20260521.htm"},"events":[{"id":8547,"run_id":7504,"accession_number":"0001503802-26-000027","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Stockholders approved the election of Class I directors (Barry E. Greene and Christy J. Oliger), amendments to the 2022 Equity Incentive Plan increasing available shares by 3,000,000, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor at the Annual Meeting held on May 21, 2026.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2467,"accession_number":"0001503802-26-000027","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2022 Equity Incentive Plan increasing available shares by 3,000,000, and the Compensation Committee's approval of a broad-based retention program granting performance-based restricted stock units (PSUs) to named executive officers (Richard Paulson, Dr. Reshma Rangwala, Lori Macomber, Stuart Poulton) and the CFO. The specific PSU grants to executives with defined vesting conditions tied to clinical milestones constitute material compensatory arrangements under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:36.785990+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2468,"accession_number":"0001503802-26-000027","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of an Annual Meeting of stockholders held on May 21, 2026, including election of Class I directors (Barry E. Greene and Christy J. Oliger), approval of equity plan amendments, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing directly matches the shareholder_vote_results taxonomy entry, which covers results of votes at annual or special meetings of security holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:36.785990+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2467,"accession_number":"0001503802-26-000027","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2022 Equity Incentive Plan increasing available shares by 3,000,000, and the Compensation Committee's approval of a broad-based retention program granting performance-based restricted stock units (PSUs) to named executive officers (Richard Paulson, Dr. Reshma Rangwala, Lori Macomber, Stuart Poulton) and the CFO. The specific PSU grants to executives with defined vesting conditions tied to clinical milestones constitute material compensatory arrangements under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:36.785990+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-05-28"},{"id":2468,"accession_number":"0001503802-26-000027","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of an Annual Meeting of stockholders held on May 21, 2026, including election of Class I directors (Barry E. Greene and Christy J. Oliger), approval of equity plan amendments, advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing directly matches the shareholder_vote_results taxonomy entry, which covers results of votes at annual or special meetings of security holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:47:36.785990+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-05-28"}]}